top of page

ABOUT

Normin Health 

Normin Health was founded by Dr. Wendong Chen in 2012. Since its inception, the company launched its first observational study using hospital data to assess treatment outcomes and hospital costs associated with first-line and second-line chemotherapy in patients with non-squamous non-small cell lung cancer. Building on the significant success of this initial project, Normin Health has established a highly specialized team to conduct real-world studies and develop health economic models. These efforts aim to address the evidence needs for developing market access strategies, supporting reimbursement submissions, and driving commercial promotions.

​

Normin Health has collaborated with numerous international pharmaceutical and medical device companies, including Eli Lilly, Xian Janssen, BMS, Novartis Oncology, Gilead, Celgene, J&J, and BD. The company has earned high recognition from its clients for its professionalism, innovation, and quality of service. In addition to its existing services, Normin Health is actively expanding into new business areas to better address market access needs. These initiatives include developing mobile app communication tools to effectively convey the clinical and economic value of medical products and creating patient follow-up apps to bridge gaps in real-world data collection.

Team
Founder of Normin Health 
wdc.webp
Wendong Chen, MD, PhD

          wendong.chen@normin.ca 

Dr. Wendong Chen graduated with a bachelor's degree from Beijing Medical University (now Peking University Health Science Center) and earned his PhD in Health Outcomes and Health Economics from the University of Toronto, Canada. Dr. Chen is a renowned scholar in the fields of real-world research and health economics. He currently serves as a researcher at the University of Toronto’s Health Technology Assessment Center and is also a visiting professor at Xiangya Hospital, Central South University. With extensive experience in health economics analysis and real-world data research on common cancers and chronic diseases, Dr. Chen is dedicated to translating scientific findings into practical applications to advance medical development and optimize public health policies.

​

In terms of academic achievements, Dr. Chen has gained widespread recognition in the international medical community for his innovative research methods and rigorous academic approach. He specializes in synthesizing existing literature evidence and analyzing large-scale real-world patient data to quantify disease burden, evaluate the effectiveness of medical technologies, and assess their cost-effectiveness using health economics models. These efforts provide high-quality evidence for clinical medicine and health policy formulation. To date, Dr. Chen has published over 60 high-impact academic papers in top international medical journals, including JAMA. Many of these publications have significantly influenced the fields of health technology assessment and cost-effectiveness analysis.

​

Beyond his academic research, Dr. Chen actively engages in the international academic community, holding several important academic positions. He is a senior researcher at the University of Toronto’s Health Technology Assessment Center, where he regularly provides consulting and guidance for health technology assessment projects. As a visiting professor at Xiangya Hospital, Central South University, he is committed to advancing health economics and real-world research in China. In academic editing, Dr. Chen serves as an editorial board member for Scientific Reports, a journal under the Nature portfolio, where he reviews and supervises peer-reviewed research to maintain high academic standards. Furthermore, Dr. Chen has extensive academic influence in the field of international health economics. He has frequently served as a reviewer for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Conferences, contributing to frontier discussions and scholarly reviews in global health economics and outcomes research.

Publications of Normin Health 

  1. Yu D, Wang D, Chen Y, Dong T, Zhang Y, Huang M, Wu A, Ouyang Y, Chen W, Qian Z. Impact of coronavirus disease 2019 on the utilization of hospital services and development of optimal pandemic control strategy in Chinese tertiary hospitals during the Omicron wave. BMC Health Services Research. 2024 Jul 23;24(1):833.  PMID: 39044202

  2. Kuang Y, Li Y, Lv C, Li M, Zhang Z, Chen Y, Chen W, Wang X, Ba L, Zhong Y, Feldman S. Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China. Dermatology and Therapy. 2024 May 11:1-3. PMID: 38733512

  3. Ma J, Zhao D, Zhen B, Xia Y, Gong Q, Chen W. Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma. Journal of Comparative Effectiveness Research. 2023 Dec;12(12):e230073.PMID: 37916709

  4. Li J, Zhou G, Li X, Huang S, Lin H, Lin S, Tan L, Chen W, Huang X, Wang Y. Comparisons of procedural characteristics and clinical outcomes between SMARTTOUCH SURROUNDFLOW catheter and other catheters for atrial fibrillation radiofrequency catheter ablation: a systematic literature review. BMJ open. 2023 Oct 1;13(10):e075579. PMID: 37848300

  5. Zeng R, Pu X, Chen S, Chen C, Chen Y, Chen W, Fu H. Oropharynx pain, discomfort, and economic impact of transesophageal echocardiography for planned radio-frequency catheter ablation in patients with atrial fibrillation: A cross-sectional survey study. IJC Heart & Vasculature. 2023 Oct 1;48:101266. PMID: 37719868

  6. Zhao Y, Zhang C, Peng L, Xie Q, Chen C, Yan L, Chen W. Clinical effectiveness and efficiency of a new steerable sheath technology for radiofrequency ablation in Chinese patients with atrial fibrillation: a retrospective comparative cohort study. Journal of Thoracic Disease. 2023 Jul 7;15(7):3953. PMID: 37559613

  7. Jiang Q, Wang W, Chen W, Xu Y. The impact of cognitive impairment on disease burden in Chinese patients with multiple sclerosis: A model simulation study. Multiple Sclerosis and Related Disorders. 2023 May 1;73:104626. PMID: 36966649

  8. Hu K, Zhang M, Yang J, Wang Q, Tan M, Deng S, Chen J, Zhu W, Chen W, Kuang Y, Chen X. Should we customize the treatment with interleukin-17A inhibitors for moderate-to-severe psoriasis in the real-world setting?. Journal of the European Academy of Dermatology and Venereology: JEADV. 2023 Feb;37(2):e262-3. PMID: 36268702

  9. Cao, Yang, Fang Xiong, Xiaozhe Xia, Pengjuan Gu, Qinghong Wang, Aiping Wu, Huan Zhan, Wendong Chen, and Zhaoxin Qian. Economic impact of powered stapler in video-assisted thoracic surgery lobectomy for lung Cancer in a Chinese tertiary hospital: a cost-minimization analysis. Health Economics Review 2022; 12(1): 1-13. PMID: 35141818

  10. Yang Gao, Fang Xiong, Xiaozhe Xia, Pengjuan Gu, Qinghong Wang, Aiping Wu, Huan Zhan, Wendong Chen, and Zhaoxin Qian. Clinical outcomes of powered and manual staplers in video-assisted thoracic surgery lobectomy for lung cancer. Journal of Comparative Effectiveness Research 2021; 10(13):1011-9. PMID: 34189927

  11. Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474. PMID: 33244205

  12.  Chen H, Shi J, Pan Y, et al. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China[J]. Advances in Therapy, 2020, 37(1): 431-449.

  13. Zhong Q, Tan Y, Chen W, et al. Disease burden of schizophrenia patients visiting a Chinese regional mental health centre. J Comp Eff Res. 2020;9(7):469-481.

  14. Lu J, Chen W. Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China. Journal of comparative effectiveness research. 2019 Jun 24.

  15. Zhaoxin Qian, Yinhuai Wang, Zhengyan Tang, Da Ren, Zhao Wang, Wendong Chen & Zhihong Li. Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings. Journal of medical economics 2019. 22(8):728-735.

  16. Ke X, Du Y, Zheng Y, Su L, Chen Y, Zhang Y, Chen K, Cheng Y, Chen W. Risk factors for the difficulties in general activities across the day in Chinese children and adolescents with attention-deficit/hyperactivity disorder. Neuropsychiatric disease and treatment. 2019;15:157.

  17. Yu Z, Liu Y, Cui Y, Ma R, Zhan H, Chen W, Liu H. Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China. Journal of comparative effectiveness research. 2019 Mar 29;8(7):487-95.

  18. Wu Y, Wu Y, Gangoli G, Bourcet A, Danker III W, Gong Q, Zhan H, Chen W, Wang Z. Using flowable gelatin in anterior cervical spine surgery in real-world practice: a retrospective cohort study. Journal of comparative effectiveness research. 2019 Jan 24;8(5):317-26.

  19. Yan F, Yang Y, Huang Q, Chen Y, Jia P, Chen W, Ma X. Cost-effectiveness of a free drug program for schizophrenia in Beijing, China. International Journal of Social Psychiatry. 2019 Feb;65(1):28-37.

  20.  Bing Wu, Kai Song, Qianyi Gong, Huan Zhan, Wendong Chen & Zheng Wang. Perioperative outcomes and hospital costs associated with flowable gelatin hemostatic matrix for lumbar surgeries in the real-world hospital setting, Journal of Medical Economics 2019, 22(9):917-923

  21. Du Y, Zheng Y, Ke X, Su L, Coghill D, Chen Y, Zhang Y, Yuan Z, Cheng Y, Chen W. Validity and reliability of the Dundee difficult times of the day scale in Chinese children and adolescents with attention-deficit/hyperactivity disorder. Journal of comparative effectiveness research. 2018 Nov 23;8(1):33-44.

  22. Li J, Liu Q, Chen Y, Gao S, Zhang J, Yang Y, Chen W. Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis. Journal of medical economics. 2017 Jan 2;20(1):91-7.

  23. Li J, Wen Z, Cai A, Tian F, Zhang L, Luo X, Deng L, He J, Yang Y, Chen W. Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. Journal of comparative effectiveness research. 2017 May;6(3):205-18.

  24. Chen J, Wu S, Hu C, Yang Y, Rajan N, Chen Y, Yang C, Li J, Chen W. Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study. ClinicoEconomics and outcomes research: CEOR. 2016;8:97.

  25. Chen W, Yang Y, Chen Y, Du F, Zhan H. Cost-effectiveness of bortezomib for multiple myeloma: a systematic review. ClinicoEconomics and outcomes research: CEOR. 2016;8:137.

  26. Li X, Wang Y, Wang Y, Chen J, Wu S, Hu C, Yang Y, Rajan N, Papadimitropoulos M, Chen Y, Peng T. Supportive care costs associated with second-line chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. Drugs-real world outcomes. 2015 Mar 1;2(1):87-97.

  27. Wang Y, Chen J, Wu S, Hu C, Li X, Wang Y, Yang Y, Rajan N, Chen Y, Chen Y, Luo Z. Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study. BMC Cancer. 2014 Dec;14(1):940.

  28. Hu C, Wang Y, Chen J, Wu S, Li X, Wang Y, Yang Y, Rajan N, Papadimitropoulos M, Xiao Q, Zhan H. Tumor response and clinical toxicity associated with second‐line chemotherapy regimens for advanced non‐squamous non‐small cell lung cancer: A retrospective cohort study. Thoracic Cancer. 2014 Sep;5(5):365-76.

  29. Song Y, Yang Y, Chen W, Liu W, Wang K, Li X, Wang K, Papadimitropoulos M, Montgomery W. Clinical response and hospital costs associated with the empirical use of vancomycin and linezolid for hospital-acquired pneumonia in a Chinese tertiary care hospital: a retrospective cohort study. ClinicoEconomics and outcomes research: CEOR. 2014;6:451.

Need more details? Contact us

We are here to assist. Contact us by phone, email or via our Social Media channels.

bottom of page